"advanced lung cancer" trang 7 - tải miễn phí từ tailieunhanh
Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)
8    49    1
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials
17    86    0
Prototype edge-grown nanowire sensor array for the real-time monitoring and classification of multiple gases

Prototype edge-grown nanowire sensor array for the real-time monitoring and classification of multiple gases
8    52    1
Implantation of 125I radioactive seeds via c-TBNA combined with chemotherapy in an advanced non-small-cell lung carcinoma patient

Implantation of 125I radioactive seeds via c-TBNA combined with chemotherapy in an advanced non-small-cell lung carcinoma patient
5    42    1
Long-term survival of an elderly patient with advanced gastric cancer after combination therapy: A case report and literature review

Long-term survival of an elderly patient with advanced gastric cancer after combination therapy: A case report and literature review
7    80    0
The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma

The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma
9    50    1
Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: A retrospective study

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: A retrospective study
10    77    1
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
9    37    1
Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
9    56    1
Baseline C-reactive protein predicts efcacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: A retrospective, multicenter study

Baseline C-reactive protein predicts efcacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: A retrospective, multicenter study
10    1    1
Báo cáo y học:

Báo cáo y học: "Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients"
6    70    0
Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinumbased chemotherapy: A meta-analysis based on the PRISMA statement

Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinumbased chemotherapy: A meta-analysis based on the PRISMA statement
13    59    1
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: The INCREASE trial

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: The INCREASE trial
10    63    1
Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors

Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors
10    39    1
Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: A retrospective cohort study

Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: A retrospective cohort study
17    36    1
Clinical and economic impact of ‘ROS1- testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

Clinical and economic impact of ‘ROS1- testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain
13    27    1
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
10    16    1
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
22    4    1
Prognostic value of CYFRA 21−1 and Ki67 in advanced NSCLC patients with wild-type EGFR

Prognostic value of CYFRA 21−1 and Ki67 in advanced NSCLC patients with wild-type EGFR
10    3    1
Pan-immune-inflammation and its dynamics: Predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy

Pan-immune-inflammation and its dynamics: Predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy
11    6    1